Repligen

#1716

Rank

$8.65B

MarketCap US

US United States

Country

Summary
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

History

Since its founding in 1982, Repligen has been developing breakthrough technologies for the bioprocessing industry. As the leader in providing downstream and materials production technologies, we have become instrumental in enabling the growth of the world's top biotech companies. Our customers depend on the reliability and reproducibility of our products, which help them reduce process variability and maximize quality in their bioprocessing applications.


Mission
Repligen's mission is to empower our customers to manufacture life-saving drugs and therapeutics efficiently, reliably and safely.

Vision
Repligen's vision is to be the global leader in bioprocessing and materials sciences, providing innovative solutions to our customers that enable success in drug discovery, development and production.

Key Team

Ms. Christine Gebski (Sr. VP of Filtration & Chromatography)

Mr. Ralf Kuriyel (Sr. VP of R&D)

Ms. Sondra S. Newman (Global Head of Investor Relations)

Ms. Kimberly Cornwell (Global Head of Legal & Gen. Counsel)

Mr. Stephen Tingley (VP & Head of Global Sales)

Ms. Rachel Goodrich (VP of Marketing)

Mr. Craig Harrison (Sr. VP of Process Analytics)


Recognition and Awards
Repligen was recently named the Leader in Bioprocess Controllers and Systems by Frost & Sullivan and was recognized as the Pew Charitable Trusts Breakthrough Science and Technology Research Award.

References
Repligen
Leadership team

Mr. Anthony J. Hunt (Pres, CEO & Director)

Mr. Jon K. Snodgres (Chief Financial Officer)

Mr. James R. Bylund (Chief Operating Officer)

Products/ Services
Biotechnology, Consumer Goods, Health Care, Manufacturing, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Waltham, Massachusetts, United States
Established
1981
Company Registration
SEC CIK number: 0000730272
Net Income
100M - 500M
Revenue
500M - 1B
Traded as
RGEN
Social Media
Sun Mar 03 2024
About

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with
Logo

Copyright 2023 © businessabc powered by ztudium